Keywords
Carcinoma, Non-Small-Cell Lung ×
Eligibility Determination ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

45 Search results.

Vargatef 2nd line therapy in NSCLC NCT02392455 - Eligibility Criteria

- 5/14/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT02392455 Brief Summary: This observational study will investigate the efficacy and tolerability of Vargatef (Nintedanib) plus docetaxel in daily routine second-line treatment in patients with locally advanced, metastatic or locally recurrent NSCLC. Treatment with Vargatef in eligible NSCLC patients, for whom the treating physician has decided to initiate treatment with Vargatef in second line according to the local label, will be observed for up to 24 months. Survial follow-up will be done until the end of the study.

Eligibility Carcinoma, Non-Small Cell Lung NCT02098954

- 1/15/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers; ODM derived from: https://clinicaltrials.gov/show/NCT02098954

Eligibility Carcinoma, Non Small Cell Lung NCT02135211

- 1/15/19 - 1 form, 1 itemgroup, 11 items, 1 language
Itemgroup: Criteria
Healthy Directions After Lung Surgery Pilot; ODM derived from: https://clinicaltrials.gov/show/NCT02135211

Eligibility Chemotherapeutic Agent Toxicity NCT01097317

- 11/27/17 - 1 form, 1 itemgroup, 12 items, 1 language
Itemgroup: Criteria
First-Line Chemotherapy With or Without Neuromuscular Electrical Stimulation in Treating Patients With Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01097317

Eligibility Carcinoma, Non-Small-Cell Lung NCT00993499

- 11/17/17 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib; ODM derived from: https://clinicaltrials.gov/show/NCT00993499

Eligibility Carcinoma, Non-Small-Cell Lung NCT01022671

- 11/17/17 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With Chemotherapy; ODM derived from: https://clinicaltrials.gov/show/NCT01022671

Eligibility Carcinoma, Non-Small-Cell Lung NCT00979576

- 11/17/17 - 1 form, 2 itemgroups, 48 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT00979576

Eligibility Carcinoma, Non-Small-Cell Lung NCT00835471

- 11/16/17 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC); ODM derived from: https://clinicaltrials.gov/show/NCT00835471

Eligibility Carcinoma, Non-Small-Cell Lung NCT00824408

- 11/16/17 - 1 form, 2 itemgroups, 30 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC; ODM derived from: https://clinicaltrials.gov/show/NCT00824408

Eligibility Carcinoma, Non-Small-Cell Lung NCT00730925

- 11/15/17 - 1 form, 2 itemgroups, 29 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients; ODM derived from: https://clinicaltrials.gov/show/NCT00730925

Eligibility Carcinoma, Non-Small-Cell Lung NCT00791336

- 11/15/17 - 1 form, 2 itemgroups, 21 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study to Evaluate Using Nelfinavir With Chemoradiation for Non-small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00791336

Eligibility Carcinoma, Non-Small-Cell Lung NCT00806819

- 11/15/17 - 1 form, 2 itemgroups, 26 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC; ODM derived from: https://clinicaltrials.gov/show/NCT00806819